RecruitingNot ApplicableNCT07632742

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial


Sponsor

Northwestern University

Enrollment

180 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 100 Years

Inclusion Criteria2

  • Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
  • Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)

Exclusion Criteria4

  • Patients who lack decisional capacity
  • Patients unable to read/speak English
  • Patients who are on a blood thinner (anticoagulation medication)
  • Patients who do not have internet access to complete postoperative surveys

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMagneto 150 holmium laser

The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser

DEVICEMoses 2.0 holmium laser

The HoLEP procedure will be performed using the Moses 2.0 holmium laser


Locations(1)

Northwestern University

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07632742


Related Trials